amifostine anhydrous has been researched along with Colorectal Cancer in 13 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential." | 9.07 | Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. ( Baker, L; Gullo, JJ; Leming, PD; Lokich, JJ; LoRusso, P; McCulloch, W; Poplin, EA; Schein, P; Schulz, JJ; Veach, SR, 1994) |
| "Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)." | 7.72 | Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003) |
| "The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential." | 5.07 | Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. ( Baker, L; Gullo, JJ; Leming, PD; Lokich, JJ; LoRusso, P; McCulloch, W; Poplin, EA; Schein, P; Schulz, JJ; Veach, SR, 1994) |
| "Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)." | 3.72 | Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003) |
| " Professionals discussed a novel treatment (Irinotecan) for advanced colorectal cancers; a unique anticancer agent (Docetaxel) effective in hard-to-treat head and neck cancer; a highly active neoadjuvant chemotherapy regimen for operable breast cancer; and a cytoprotective agent (Amifostine) capable of protecting normal tissue from radiation and chemotherapeutic toxicity." | 3.69 | Highlights of the Eighth European Cancer Conference. ( Prescott, LM, 1995) |
| " In this study, the pharmacokinetic parameters of 5-FU are monitored in six patients, who received two chemotherapeutic courses of 2,600 mg/m2 BSA 5FU over 24 h, one course with 700 mg/m2 BSA amifostine prior to the 5-FU infusion and the other without." | 1.31 | Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma. ( Fuhlroth, J; Martens-Lobenhoffer, J; Ridwelski, K, 2000) |
| " As the dosage of 90Y-CO17-1A increased, the rate of tumor growth decreased, but all experimental animals in this group died between 14 and 21 days." | 1.28 | Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques. ( Byrd, BL; Crook, JE; Holloway, EC; Lee, YC; Steplewski, Z; Sun, TT; Washburn, LC, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouhadjari, N | 1 |
| Gabato, W | 1 |
| Calabrese, D | 1 |
| Msika, S | 1 |
| Keita, H | 1 |
| Dziegielewski, J | 1 |
| Baulch, JE | 1 |
| Goetz, W | 1 |
| Coleman, MC | 1 |
| Spitz, DR | 1 |
| Murley, JS | 2 |
| Grdina, DJ | 2 |
| Morgan, WF | 2 |
| Tsavaris, N | 1 |
| Kosmas, C | 1 |
| Vadiaka, M | 1 |
| Zonios, D | 1 |
| Papalambros, E | 1 |
| Papantoniou, N | 1 |
| Margaris, H | 1 |
| Zografos, G | 1 |
| Rokana, S | 1 |
| Retalis, G | 1 |
| Koufos, C | 1 |
| Wakelee, H | 1 |
| Fisher, GA | 1 |
| Kataoka, Y | 1 |
| Baker, KL | 1 |
| Diamond, AM | 1 |
| Kowalski, T | 1 |
| Maier, C | 1 |
| Reinacher-Schick, A | 1 |
| Schlegel, U | 1 |
| Poplin, EA | 1 |
| LoRusso, P | 1 |
| Lokich, JJ | 1 |
| Gullo, JJ | 1 |
| Leming, PD | 1 |
| Schulz, JJ | 1 |
| Veach, SR | 1 |
| McCulloch, W | 1 |
| Baker, L | 1 |
| Schein, P | 1 |
| Fahlke, J | 1 |
| Ridwelski, K | 2 |
| Lippert, H | 1 |
| Martens-Lobenhoffer, J | 1 |
| Fuhlroth, J | 1 |
| Penz, M | 1 |
| Kornek, GV | 1 |
| Raderer, M | 1 |
| Ulrich-Pur, H | 1 |
| Fiebiger, W | 1 |
| Scheithauer, W | 1 |
| Prescott, LM | 1 |
| Delioukina, ML | 1 |
| Prager, D | 1 |
| Parson, M | 1 |
| Hecht, JR | 1 |
| Rosen, P | 1 |
| Rosen, LS | 1 |
| Lee, YC | 1 |
| Washburn, LC | 1 |
| Sun, TT | 1 |
| Byrd, BL | 1 |
| Crook, JE | 1 |
| Holloway, EC | 1 |
| Steplewski, Z | 1 |
1 review available for amifostine anhydrous and Colorectal Cancer
| Article | Year |
|---|---|
[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].
Topics: Adrenergic Uptake Inhibitors; Amifostine; Animals; Antineoplastic Agents; Antineoplastic Combined Ch | 2008 |
4 trials available for amifostine anhydrous and Colorectal Cancer
| Article | Year |
|---|---|
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasm | 2005 |
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.
Topics: Adult; Aged; Amifostine; Bone Marrow Diseases; Colorectal Neoplasms; Female; Humans; Male; Middle Ag | 1994 |
High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma.
Topics: Amifostine; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combinat | 1999 |
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Pro | 2002 |
8 other studies available for amifostine anhydrous and Colorectal Cancer
| Article | Year |
|---|---|
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P | 2016 |
WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability.
Topics: Amifostine; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Radia | 2008 |
Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Amifostine; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea | 2003 |
Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha.
Topics: Amifostine; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; | 2007 |
Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Injections, Su | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Mo | 1995 |
Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
Topics: Amifostine; Animals; Antibodies, Monoclonal; Cell Division; Cell Line; Chelating Agents; Colorectal | 1990 |